Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO
Author:
- 22 April 2022
- journal article
- editorial
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 53 (5) , 361-365
Abstract
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.Keywords
This publication has 17 references indexed in Scilit:
- Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in DiseasesThe American Journal of Pathology, 2020
- Oxygen sensing and adaptability won the 2019 Nobel Prize in Physiology or medicineGenes & Diseases, 2019
- Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical ExperienceAdvances in Chronic Kidney Disease, 2019
- Alternatives to Intention-to-Treat Analyses—ReplyJAMA, 2019
- Beware of on-treatment safety analysesClinical Trials, 2018
- What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?Current Opinion in Nephrology and Hypertension, 2010
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2009
- Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomesKidney International, 2008
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998